Eli Lilly and Company (NYSE:LLY) Shares Purchased by MJP Associates Inc. ADV

MJP Associates Inc. ADV grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 37.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,215 shares of the company’s stock after purchasing an additional 602 shares during the quarter. MJP Associates Inc. ADV’s holdings in Eli Lilly and Company were worth $1,039,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Norges Bank acquired a new position in Eli Lilly and Company during the fourth quarter worth $3,416,206,000. Moneta Group Investment Advisors LLC raised its holdings in shares of Eli Lilly and Company by 102,752.2% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock worth $1,992,374,000 after acquiring an additional 5,440,731 shares during the period. Morgan Stanley grew its holdings in shares of Eli Lilly and Company by 44.1% in the fourth quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock valued at $4,411,740,000 after purchasing an additional 3,691,436 shares during the period. Envestnet Asset Management Inc. increased its position in Eli Lilly and Company by 316.9% during the first quarter. Envestnet Asset Management Inc. now owns 2,434,073 shares of the company’s stock worth $217,569,000 after purchasing an additional 1,850,187 shares during the last quarter. Finally, Mizuho Markets Americas LLC raised its stake in Eli Lilly and Company by 2,882.6% during the first quarter. Mizuho Markets Americas LLC now owns 1,765,702 shares of the company’s stock worth $18,090,000 after purchasing an additional 1,706,502 shares during the period. Hedge funds and other institutional investors own 81.38% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the subject of a number of recent analyst reports. Citigroup raised their price target on shares of Eli Lilly and Company from $360.00 to $525.00 and gave the stock a “buy” rating in a report on Wednesday, July 26th. Truist Financial lifted their target price on Eli Lilly and Company from $525.00 to $600.00 and gave the company a “buy” rating in a research report on Wednesday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating and set a $630.00 price target on shares of Eli Lilly and Company in a report on Tuesday, September 5th. Berenberg Bank boosted their price objective on shares of Eli Lilly and Company from $375.00 to $500.00 in a report on Tuesday, June 20th. Finally, StockNews.com began coverage on shares of Eli Lilly and Company in a research note on Thursday, August 17th. They set a “buy” rating for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twenty have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $532.78.

Eli Lilly and Company Stock Down 0.3 %

Shares of LLY traded down $1.89 during midday trading on Monday, hitting $573.77. The company had a trading volume of 1,261,913 shares, compared to its average volume of 3,028,961. The company’s 50-day simple moving average is $512.56 and its 200-day simple moving average is $439.28. The company has a debt-to-equity ratio of 1.63, a quick ratio of 0.87 and a current ratio of 1.13. Eli Lilly and Company has a 1 year low of $296.32 and a 1 year high of $601.84. The firm has a market capitalization of $544.67 billion, a P/E ratio of 79.56, a P/E/G ratio of 2.44 and a beta of 0.32.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, August 8th. The company reported $2.11 EPS for the quarter, topping the consensus estimate of $1.98 by $0.13. The company had revenue of $8.31 billion during the quarter, compared to analysts’ expectations of $7.58 billion. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The firm’s revenue was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.25 EPS. As a group, sell-side analysts expect that Eli Lilly and Company will post 9.84 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th were issued a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date was Monday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 62.87%.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 107,022 shares of the stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $459.28, for a total value of $49,153,064.16. Following the transaction, the insider now directly owns 101,248,810 shares in the company, valued at $46,501,553,456.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Eli Lilly and Company news, EVP Alonzo Weems sold 1,148 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $590.98, for a total transaction of $678,445.04. Following the transaction, the executive vice president now owns 7,760 shares of the company’s stock, valued at $4,586,004.80. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 107,022 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $459.28, for a total value of $49,153,064.16. Following the completion of the sale, the insider now owns 101,248,810 shares of the company’s stock, valued at approximately $46,501,553,456.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,010,309 shares of company stock valued at $21,095,701,670. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.